Skip to main content

Epidermolysis Bullosa

EDM (Early Day Motion) 302: tabled on 18 July 2022

Tabled in the 2022-23 session.

This motion has been signed by 21 Members. It has not yet had any amendments submitted.

Motion text

That this House welcomes the recent identification of anti-inflammatory drugs, which are already available within the NHS, that could be successful in treating Epidermolysis Bullosa (EB); notes that around 5,000 people in the UK are currently living with EB, a group of rare genetic disorders that result in fragile and blistered skin; recognises the work of DEBRA in spending £1.8 million on charitable activities in 2021, including nearly £500,000 on research projects; and further welcomes DEBRA’s drug repurposing programme, which requires the Government to commit £10 million of financial support to accelerate clinical trials and secure approved treatments for EB sufferers in the UK.

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.

In addition to the sponsors, the following Members have signed to support the motion.

There are no withdrawn signatures for this motion.